Achieving BP goals with valsartan and HCTZ alone and in combination: Pooled analysis of two randomized, double-blind, placebo-controlled studies

Current Medical Research and Opinion

Volumn 24, Issue 9, 2008, Pages 2617-2626

  Nash, David T ^a,c   Crikelair, Nora ^b   Zappe, Dion ^b  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c Syracuse Preventive Cardiology   (United States)

Author keywords

Angiotensin receptor blocker; Combination therapy; Hypertension; Pooled analysis; Thiazide diuretic; Valsartan

Indexed keywords

HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; PLACEBO; VALSARTAN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BACKACHE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; BODY MASS; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GOAL ATTAINMENT; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; NAUSEA; OBESITY; PERIPHERAL EDEMA; POPULATION RESEARCH; POTASSIUM BLOOD LEVEL; RACE DIFFERENCE; RHINOPHARYNGITIS; SIDE EFFECT; SYNCOPE; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION;

ADULT; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIURETICS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; PLACEBOS; RETROSPECTIVE STUDIES; TETRAZOLES; VALINE;

EID: 53349146082     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007990802333282     Document Type: Article

References (24)

1. Chobanian AV, Bakris GL, Black HR, et al., and the National High Blood Pressure Education Program Coordinating Committee. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003;42:1206-52
2. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97.
3. Sharma AM, Engeli S. Managing big issues on lean evidence: treating obesity hypertension. Nephrol Dial Transplant 2002; 17:353-5
4. Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs 2002;62:443-62
5. Weber MA. Creating a combination antihypertensive regimen: what does the research show? J Cin Hypertens (Greenwich) 2003;5(Suppl 3):12-20
6. Mallion J-M, Carretta R, Trenkwalder P, et al., on behalf of the Co-Diovan Study Group. Valsartan/hydrocholorothiazide is effective in hypertensive patients inadequately controlled by valsartan monotherapy. Blood Press 2003;12(Suppl 1):36-43
7. Lacourcière Y, Poirier L, Hebert D, et al. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial. Clin Ther 2005; 27:1013-21
8. Mimran A, Weir MR. Angiotensin-receptor blockers and diuretics: advantages of combination. Blood Press 2005;14:6-11
9. Palatini P. Combination therapy in the management of hypertension: focus on angiotensin receptor blockers combined with diuretics. J Clin Hypertens (Greenwich) 2005;7:96-101
10. Benz JR, Black HR, Graff A, et al. Valsartan and hydrochlorothiazide in patients with essential hypertension: a multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy. J Hum Hypertens 1998;12: 861-66
11. Zillich AJ, Garg J, Basu S, et al. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension 2006;48:219-24
12. Pool JL, Glazer R, Weinberger M, et al. Comparison of valsartan/ bydrochlorothiazide combination therapy at doses up to 320/25mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults. Clin Ther 2007;29:61-73
13. Harrell FE. Regression modeling strategies with applications to linear models, logistic regression, and survival analysis. New York: Springer, 2001
14. Faraway JJ. On the cost of data analysis. J Computational and Graphical Statistics 1992;1:213-29
15. Moyé LA. Statistical reasoning in medicine: the intuitive p value primer. New York: Springer, 2000
16. Poole C. Beyond the confidence interval. Am J Public Health 1987;77:195-99
17. Gardner MJ, Altman DG. Confidence intervals rather than p values: estimation rather than hypothesis testing. BMJ 1986; 292:746-50
18. Lang JM, Rothman KJ, Cann CI. That confounded p-value. Epidemiology 1998;9:7-8
19. Van Belle G. Statistical rules of thumb. Wiley series in probability and statistics. New York: John Wiley & Sons, 2002
20. Basile JN, Chrysant S. The importance of early antihypertensive efficacy: the role of angiotensin II receptor blocker therapy. J Hum Hypertens 2006;20:169-75
21. Staessen JA, Thijs L, Fagard R, et al., for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe trial. J Hypertens 2004;22:847-57
22. Caro JJ, Salas M, Speckman JL, et al. Persistence with treatment for hypertension in actual practice. CMAJ 1999; 160:31-7
23. Caro JJ, Speckman JL, Salas M, et al. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. CMAJ 1999;160:41-6
24. Payne KA, Esmonde-White S. Observational studies of antihypertensive medication use and compliance: is drug choice a factor in treatment adherence? Curr Hypertens Rep 2000; 2:515-24